Prevalence and determinants of low testosterone levels in men with type 2 diabetes mellitus; a case-control study in a district hospital in Ghana

Dorcas Serwaa; Folasade Adenike Bello; Kayode O Osungbade; Charles Nkansah; Felix Osei-Boakye; Samuel Kwasi Appiah; Maxwell Hubert Antwi; Mark Danquah; Tonnies Abeku Buckman; Ernest Owusu

doi:10.1371/journal.pgph.0000052

. 2021 Dec 2;1(12):e0000052. doi: 10.1371/journal.pgph.0000052

Prevalence and determinants of low testosterone levels in men with type 2 diabetes mellitus; a case-control study in a district hospital in Ghana

Dorcas Serwaa ^1,^2,^*, Folasade Adenike Bello ^3,⁴, Kayode O Osungbade ⁵, Charles Nkansah ⁶, Felix Osei-Boakye ⁷, Samuel Kwasi Appiah ⁶, Maxwell Hubert Antwi ⁸, Mark Danquah ⁷, Tonnies Abeku Buckman ⁹, Ernest Owusu ¹⁰

Editor: Palash Chandra Banik¹¹

¹Department of Obstetrics and Gynecology, College of Medicine, Pan African University, Yaoundé, Cameroun

²Institute of Life and Earth Sciences, University of Ibadan, Ibadan, Nigeria

³Department of Obstetrics and Gynaecology, University College Hospital, Ibadan, Oyo State, Nigeria

⁴Department of Obstetrics and Gynaecology, University of Ibadan, Ibadan, Oyo State, Nigeria

⁵Department of Community Medicine, College of Medicine, University College Hospital, Oyo State, Nigeria

⁶Department of Biomedical Laboratory Sciences, School of Allied Health Sciences, University for Development Studies, Tamale, Ghana

⁷Department of Medical Laboratory Technology, Faculty of Applied Science and Technology, Sunyani Technical University, Sunyani, Ghana

⁸Department of Medical Laboratory, Nkenkaasu District Hospital, Nkenkaasu, Ghana

⁹Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

¹⁰Department of Nursing and Midwifery, Methodist Health Training Institute, Afosu, Eastern Region, Ghana

¹¹Bangladesh University of Health Sciences, BANGLADESH

All authors declare that there is no competing interest.

^✉

* E-mail: dserwaa0327@stu.ui.edu.ng

Roles

Dorcas Serwaa: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing

Folasade Adenike Bello: Data curation, Investigation, Methodology, Supervision, Writing – review & editing

Kayode O Osungbade: Data curation, Formal analysis, Investigation, Supervision, Writing – review & editing

Charles Nkansah: Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

Felix Osei-Boakye: Formal analysis, Methodology, Writing – original draft, Writing – review & editing

Samuel Kwasi Appiah: Data curation, Formal analysis, Methodology

Maxwell Hubert Antwi: Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

Mark Danquah: Formal analysis, Investigation, Writing – original draft, Writing – review & editing

Tonnies Abeku Buckman: Formal analysis, Writing – original draft, Writing – review & editing

Ernest Owusu: Writing – original draft, Writing – review & editing

Palash Chandra Banik: Editor

PMCID: PMC10021198 PMID: 36962255

Abstract

Diabetes mellitus, an endocrine disorder, has been implicated in many including hypogonadism in men. Given the fact that diabetes mellitus is becoming a fast-growing epidemic and the morbidity associated with it is more disabling than the disease itself. This study sought to assess the prevalence of low testosterone levels and predictors in type 2 diabetes mellitus patients and non-diabetic men in a district hospital in Ghana. This hospital-based case-control study comprised 150 type 2 diabetics and 150 healthy men. A pre-structured questionnaire and patient case notes were used to document relevant demographic and clinical information. Venous blood sample of about 6 ml was taken to measure FBS, HbA1c, FSH, LH, and testosterone levels. All data were analyzed using STATA version 12 (STATA Corporation, Texas, USA). The overall hypogonadism in the study population was 48% (144/300). The prevalence of hypogonadism in type 2 diabetic subjects was almost three times more than in healthy men (70.7% vs 25.3%). The odds of having hypogonadism was lower in the men with normal weight and overweight with their underweight counterparts (AOR = 0.33, 95% CI; 0.12–0.96, p = 0.042) and (AOR = 0.29, 95% CI; 0.10–0.84, p = 0.023) respectively. Also, the odds of suffering from hypogonadism was lower in non-smokers compared with smokers (AOR: 0.16, 95% CI; 0.05–0.58, p = 0.005). Participants who were engaged in light (AOR: 0.29, 95% CI; 0.14–0.61, p = 0.001), moderate (AOR: 0.26, 95% CI; 0.13–0.54, p<0.001) and heavy (AOR: 0.25, 95% CI; 0.10–0.67, p = 0.006) leisure time activities had lower odds hypogonadal compared to those engaged in sedentary living. Type 2 diabetic men have high incidence of hypogonadism, irrespective of their baseline clinical, lifestyle or demographic characteristics. Smoking and sedentary lifestyle and BMI were associated with hypogonadism in the study population. Routine testosterone assessment and replacement therapy for high risk patients is recommended to prevent the detrimental effect of hypogonadism in diabetic men.

Introduction

The relationship between sex hormones and Type 2 diabetes mellitus (T2DM) is of great concern in the health sector, given the fact that diabetes mellitus is becoming a fast-growing epidemic and the morbidity associated with it is more disabling than the disease itself. Millions of people around the world are diagnosed with T2DM, many more remain undiagnosed [1]. The world prevalence of diabetes mellitus among adults (aged 20–79 years) in 2010 was 6.4% and expected to increase to 7.7%, by 2030 [2]. It is estimated that in 2000, about 7, 146, 000 people in sub-Saharan Africa had diabetes mellitus, with a projected increase to 18, 645, 000 in 2030 [3, 4]. The prevalence of diabetes mellitus in Ghana is 6.4% and about 69.9% remain undiagnosed [4]. Diabetes mellitus has been implicated in male sexual dysfunction, libido dissociations, retrograde ejaculation, erectile dysfunction and lack of efficient endocrine control of spermatogenesis [5].

Hypogonadism is characterized by low serum testosterone concentration, followed by numerous clinical features like erectile dysfunction (ED), poor morning erection, low libido, loss of memory, physical decline in strength and health, difficulty in concentration and depression [6–8]. A number of studies have shown high incidence (30–80%) of hypogonadism in men with diabetes mellitus [9–11], a clear evidence of the association between type 2 diabetes and low serum testosterone. Although mediated by a variety of mechanisms, hypogonadism is more common in diabetic than in non-diabetic men in the Western world and in Asia compared to Africa. This could be attributable to the paucity of data on this issue in sub-Saharan African men.

There are very little documented data in Ghana on the prevalence of hypogonadism in both Type 2 diabetic patients and healthy men, because of limited resources and cost-ineffectiveness of screening all men. To the best of our knowledge only one study is available on hypogonadism in diabetes mellitus men in Ghana [5]. This study, therefore, determined the prevalence of hypogonadism among Type 2 diabetic men in a district hospital in Ghana, and non-diabetic controls.

Subjects and methods

Study design and study setting

This hospital based case-control study was conducted at Nkenkaasu District Hospital located in the Offinso-North district, in the Ashanti Region, Ghana. The total land area of the Offinso-North district is about 945.9 square kilometres and lies between latitude: 7°20N. 6°50S" and longitude: 1°60W”, 1°45E". The majority of the inhabitants of this district are farmers [12]. The Nkenkaasu District Hospital serves as the main referral facility in the district and its neighboring villages. This Hospital records about 472 cases of diabetes annually, with 427 of them being T2DM, (per the outpatient department’s report).

Study participants

This study involved 150 type 2 diabetic men who had registered and receiving treatment at the diabetic clinic of Nkenkaasu Government Hospital and 150 control group comprised of apparently healthy blood donors and those visiting their relatives on admission. This study excluded patients on androgens, steroids medications, patients with a history of chronic renal failure, prostate cancer, prostatectomy and castrated men. The exclusion criteria for the healthy group was based on measurement of baseline fasting blood glucose (FBG) ≥ 7.0 mmol/l and HbA1c value ≥6% [13].

Sample size determination

The necessary sample size was obtained by employing the Kelsey’s formula: $N_{c a s e s - K e l s e y} = [\frac{r + 1}{r}] \frac{P (1 - P) {(Z_{\frac{α}{2}} + Z_{β})}^{2}}{{(p 1 - p 2)}^{2}}$ , and $P = [\frac{p 1 + (r X p 2)}{r + 1}]$ , where r is the ratio of T2DM to healthy controls, which is 1:1 in this study, $Z_{\frac{α}{2}}$ represents the critical value of the normal dispersion at α/2 (for this study at confidence level of 95%, α is 0.05 and the critical value is 1.96), Z_β represents the critical value of the normal distribution at β (this study used a power of 80%, β is 0.2 and the critical value is 0.84. p1 represents the percentage of hypogonadism in Ghanaian men with diabetes, which is 35.2%, p2 is the percentage of hypogonadism in the control group, which is 6.7% according to Asare-Anane et al. [5], and p1-p2 is the smallest difference in proportions that is clinically important.

From the formula above, the minimum number of T2DM required for this study was 33 with corresponding controls of 33. However, this study employed 300 subjects: 150 T2DM patients and 150 healthy controls.

Collection of information and patients selection

A structured questionnaire and patients’ medical records were used to document relevant demographic and clinical history from the participants. Type 2 diabetes Mellitus was diagnosed through laboratory assessment based on current WHO diagnostic criteria (FBG ≥7.0 mmol/l or 126mg/dl) and HbA1c of <6.0% [13] and confirmed through a physician’s recommendations.

Anthropometric variables measurements

Body mass index

Height to the nearest centimetre without shoes and weight to the nearest 0.1 kg in light clothing was estimated. Participants were weighed on a bathroom scale and their heights were measured with a wall-mounted ruler. Body mass index (BMI) was calculated by dividing weight (kg) by height squared (m²). BMI was categorized as: <18.5 (underweight); 18.5 to 24.9 (normal weight); 25 to 29.9 (overweight); and ≥30 (obese) [13].

Blood pressure (using Korotkoff 1 and 5)

Blood pressure was measured by trained personnel using a mercury sphygmomanometer and a stethoscope. Measurements were taken from the left upper arm after participants sat >5 min in accordance with the recommendations of the American Heart Association. Duplicate measurements were taken with a 5-minutes rest interval between measurements and the mean value was recorded in mmHg. Hypertension was graded as normal when the systolic blood pressure (SBP) was >120 mm Hg and diastolic blood pressure (DBP) >80 mm Hg [14].

Physical activities

Leisure-time physical activity was measured based on alternatives to the question “How physically active are you during your leisure time?”. Subjects were characterized as having; sedentary leisure time if they perform the following activities reading, watching television, stamp collecting or other sedentary activity; Light leisure-time physical activity if subjects engage in some walking, cycling, or other physical activity under at least four hours per week; Moderate leisure-time physical activity if they perform any of the following activities running, Swimming, tennis, aerobic, heavier gardening, or similar physical activity during at least 2 hours a week; and lastly, Heavy leisure-time physical activity if engaged in heavy training or competitions in running, skiing, swimming, football, etc, which is performed regularly and several times a week [15].

Sexual health inventory for men (SHIM) questionnaire

The SHIM questionnaire is a basic 5-point questionnaire on erectile dysfunction. Each answer is graded from 0 (no sexual activity or attempts at intercourse) to 5 (very good sexual function). The maximum score patients could obtain will be 25, the minimum was 1. Based on the SHIM questionnaire patients were divided into groups: ≤22; >22 = No ED. This questionnaire was completed by all patients [16].

Health-related quality of life questionnaire

A basic health-related quality of life questionnaire (EuroQoL group / EQ-5D questionnaire) was completed by all subjects. Although this questionnaire was chosen for its brevity and simplicity. Illiterate subjects were assisted in filling the questionnaire [17].

Fasting blood glucose (FBG) measurement

Samples for FBG were analyzed using Accu-Chek Advantage Blood Glucose Monitoring System (AC; ³Roche Diagnostics, Indianapolis, IN). Calibration of the instrument was performed at 7:00 am using the test kit glucose control solution. A fingertip capillary whole blood sample was collected from each subject after overnight fasting between 7:00 am and 10:00 am for determination of fasting blood sugar and diabetes mellitus [14].

Blood sample collection

Whole venous blood of about 6 ml was obtained from each subject via a sterile venepuncture after overnight fasting between 7:00 am and 10: 00 am; 2.0 mL into EDTA for HbA1c and 4.0 mL dispensed into plain tubes at room temperature for 1 hr. after which the supernatant clear fluids were pipetted out to another tube. Plasma was separated after centrifugation (CENTRIFUGE 80–1, Japan). The clear serums were then pipetted into a clean dry test tube and separated into aliquots and frozen at -40 °ċ until analyzed for LH, FSH and testosterone [1]. Hormonal estimation was determined by an enzyme-linked immunosorbent assay (ELISA) technique using automated ELISA washer (BIO-RAD, PW40) and ELISA reader (Mindray, MR-96A) [13, 14].

Laboratory assay (FSH, LH and testosterone estimation)

All laboratory investigations were done at the Methodist Hospital Laboratory, Wenchi, Bono Region, Ghana. FSH is synthesized and secreted by gonadotrophs of the anterior pituitary gland [18]. FSH was determined using AccuDiag^™ FSH ELISA Kit (Omega Diagnostic, Scotland, UK), FSH minimum detection range for AccuDiag^™ FSH ELISA Kit is 0-200mIU/mL, specificity is 95% and sensitivity is 2.0mIU/ml. The normal reference range of FSH for the laboratory is 1.3–7.4 mIU/ml.

LH is used as an aid in the screening or monitoring of determination of evaluating fertility issues, function of reproductive organs (ovaries or testicles) [18]. LH with Kit (AccuDiag^™ LH ELISA Kit: Omega Diagnostic, Scotland, UK). The minimum detection range LH test kit is 0-200mIU/mL, specificity of 95% and 2.0mIU/ml sensitivity. Normal LH value for men according to Methodist hospital laboratory is 1.8–7.4 mIU/ml.

AccuDiag^™ Testosterone ELISA Kit (Omega Diagnostic, Scotland, UK) was used for testosterone estimation. The minimum detection limits for testosterone is 0–18 ng/ml, 95% specificity and 0.05 ng/ml sensitivity and normal range of testosterone according to the laboratory is 8.0–12.0 nmol/l.

Collecting and analysing serial serum samples eliminates variability resulting from the episodic secretion of hormones, hence this study evaluated double samples of each participant. Therefore, patients with borderline values were probably transiently suppressed by acute conditions or stress were captured appropriately upon repeat testing.

On the basis of normal ranges and international recommendations, hypogonadism in this study was described as total testosterone levels < 8 nmol/l, with or without signs and symptoms and total testosterone levels > 12 nmol/l was defined as eugonadal.

Ethical consideration and informed consent

This study was conducted based on the Helsinki Declaration and study protocol, consent forms and participant information material were reviewed and approved by University of Ibadan/University Collage Hospital Ethics Committee (UI/EC/18/0621). Also, approval was obtained from the Offinso North District Assembly and the Nkenkaasu Hospital’s Research and Ethics committee.

Written informed consent of individual participants was sought after the aims and objectives of the study had been thoroughly explained to them. Participants either signed or thumb-printed to give their consent, before the commencement of the study and they assured of the confidentiality of their data.

Statistical analysis

The data were analysed using STATA version 12 (STATA Corporation, Texas, USA). Test for normality was performed using box plot and Kolmogorov-Smirnoff test. Frequencies, percentages, means, and standard deviations were calculated to enable comparison of characteristics between T2DM subjects and the healthy group. Besides the descriptive analysis, the independent t-test was used for the comparison between the categorical and continuous variables among the groups, results were expressed as mean ± SD. Correlation analysis was performed to estimate the relationships between testosterone levels and demographic and clinical variables. Binary logistic regression analysis was done and all independent variables at p<0.10 were taken to multivariable logistic regression analysis by backward elimination to identify sociodemographic and lifestyle predictors of hypogonadism. The statistical significance of variables at final model was declared at p<0.05 and 95% confidence level for the adjusted odds ratio.

Results

Most of the study participants were aged 61–70 years 137(45.0), had normal weight 170(56.7), were engaged in farming 135(45.0), non-alcohol consumers 286(95.3), non-smokers 281(93.7), had good Health-related Quality of Life (HRQoL), 256(85.3), engaged in moderate leisure time activity 103(34.3) and had erectile dysfunction 257(85.7). There was statistically significant difference between the type 2 diabetic men and the healthy controls when categorized by age (p = 0.003), body mass index (p<0.001), smoking (p<0.001), HRQoL (p = 0.014) leisure time activity (p<0.001) and erectile function status (p<0.001) (Table 1).

Table 1. Baseline characteristics of the study participants.

Characteristics	Total	Type 2 Diabetics	Healthy controls	P value
	N (%)	N (%)	N(%)
Age (years)
41–50	88(29.3)	35(23.3)	53(35.3)	0.003*
51–60	77(25.7)	33(22.0)	44(29.3)
61–70	137(45.0)	82(54.7)	53(35.3)
BMI (kg/m ² )
Underweight	25(8.3)	20(13.3)	5(3.3)	<0.001*
Normal weight	170(56.7)	89(59.3)	81(54.0)
Overweight	91(30.3)	32(21.3)	59(39.3)
Obese	14(4.7)	9(5.0)	5(3.3)
Occupation
Farming	135(45.0)	60(40.0)	75(50.0)	0.107
Trading	47(15.7)	37(24.7)	21(140.)
Civil Servants	58(19.3)	23(15.3)	24(16.0)
Unemployed	60(20.0)	30(20.0)	30(20.0)
Alcohol consumption
Yes	14(4.7)	9(6.0)	5(3.3)	0.206
No	286(95.3)	141(94.0)	145(96.7)	0.206
Smoking
Yes	19(6.3)	19(12.7)	0(0.0)	<0.001*
No	281(93.7)	131(87.3)	150(100.0)	<0.001*
HRQoL
Poor	44(14.7)	30(20.0)	14(9.3)	0.014*
Good	256(85.3)	120(80.0)	136(90.7)	0.014*
Leisure Time Activity
Sedentary	75(25.0)	56(37.3)	19(12.7)	<0.001*
Light	92(30.7)	36(24.0)	56(37.3)
Moderate	103(34.3)	44(29.3)	59(37.3)
Heavy	30(10.0)	14(9.3)	16(10.7)
Erectile function status
No ED	43(14.3)	4(2.7)	39(26.0)	<0.001*
ED	257(85.7)	146(97.3)	111(74.0)	<0.001*

Open in a new tab

Body Mass Index (BMI), Health-related Quality of Life (HRQoL), Erectile Dysfunction (ED).

There was no statistically significant difference between the ages the type 2 diabetic men and the healthy controls (58.25±9.71 vs 56.34±9.40, p = 0.084). The body mass index (BMI) of the healthy controls was significantly higher than the type 2 diabetic men (24.01±3.38 and 23.05±4.04, p = 0.026). The type 2 diabetic men had significantly higher systolic blood pressure (SBP) (145.76±24.77 vs 134.94±25.36, p<0.001), diastolic blood pressure (DBP) (86.74±12.91 vs 82.15±9.01, p<0.001), fasting blood sugar (FBS) (10.33±5.57 vs 5.84±0.61, p<0.001) and glycated hemoglobin (HbA1c) levels (8.06±2.58 vs 4.78±0.59, p<0.001) compared with the healthy controls. The biochemical analysis revealed, mean serum follicle stimulating hormone (FSH) (8.85±5.05 vs 7.19±4.68, p = 0.003), luteinizing hormone (LH) (7.08±3.90 vs 6.18±3.58, p = 0.017) and testosterone (13.01±7.85 vs 7.66±5.45, p<0.001) levels were significantly higher in the healthy controls relative to the type 2 diabetic men (Table 2).

Table 2. Clinical and hormonal parameters of the study population.

Parameters	Type 2 Diabetics (n = 150)	Healthy controls (n = 150)	95% CI	P value
Age (yrs)	58.25±9.71	56.34±9.40	-0.258–4.084	0.084
BMI (Kg/m²)	23.05±4.04	24.01±3.38	-1.810-(-0.118)	0.026*
SBP (mmHg)	145.76±24.77	134.94±25.36	5.124–16.516	<0.001*
DBP (mmHg)	86.74±12.91	82.15±9.01	2.047–7.126	<0.001*
FBS (mmol/L)	10.33±5.57	5.84±0.61	3.588–5.394	<0.001*
HbA1C (%)	8.06±2.58	4.78±0.59	2.854–3.707	<0.001*
FSH (mIu/ml)	7.19±4.68	8.85±5.05	-2.767-(-0.555)	0.003*
LH (mIu/ml)	6.18±3.58	7.08±3.90	-1.642-(-0.162)	0.017*
Testosterone (nmol/l)	7.66±5.45	13.01±7.85	-6.887-(-3.818)	<0.001*

Open in a new tab

(Mean± SD): Body Mass Index (BMI), Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), Fasting Blood Sugar (FBS), Follicle Stimulating Hormones (FSH), Luteinizing Hormone (LH) and * mean difference is significant (p<0.05).

Correlation of testosterone (T) with fasting blood sugar among the participants

Fig 1 shows the correlation between testosterone levels and fasting blood sugar (FBG) levels among the study participants. A statistically significant positive correlation was observed between free testosterone levels and FBS (r = 0.233, p <0.001).

Correlation of testosterone (T) with glycated hemoglobin (HbA1c) among the participants

Fig 2 shows the correlation between testosterone levels and glycated haemoglobin (HbA1c) levels among the study participants. A statistically significant inverse correlation existed between the testosterone levels and HbA1c levels of the study participants (r = 0.225, p <0.001).

Prevalence of hypogonadism in the study population

Fig 3 shows the percentage distribution of testosterone levels of the diabetic and non-diabetic subjects. The overall hypogonadism in the study population was 48% (144/300). The prevalence of hypogonadism in the type 2 diabetic subjects (T< 8 nmol/l) was almost three times more than healthy men (70.7% vs 25.3%). Also, 9 (6.0%) and 39 (26%) had testosterone levels between 8–12 nmol/L for the type 2 diabetic men and non-diabetic men respectively. In addition, 35 (23.3%) and 73 (48.7%) were eugonadal for type 2 diabetic and non-diabetic men respectively. Chi square analysis revealed a statistically significant positive association between Type 2 Diabetes Mellitus and hypogonadism as indicated by the p-value from the chi-square analysis (p<0.001).

The distribution of categorized testosterone levels for the diabetic men was 70.7%, 6.0% and 23.3% for <8 nmol/L, between (8–12 nmol/L and >12 nmol/L respectively. Distribution of categorized testosterone levels for the non-diabetic group was 24.5%, 26.0% and 48.7% for < 8 nmol/L, between (8–12 nmol/L and >12 nmol/L.

Clinical and hormonal parameters of type 2 diabetic and the healthy hypogonadal men

The mean age between the type 2 diabetic and the apparently healthy hypogonadal men were not significantly different (57.48±9.62 vs 56.92±9.94, p = 0.761). Similarly, no significant differences were observed between BMI (22.94±3.98 vs 24.18±3.92, p = 0.099), SBP (144.42±23.39 vs 134.50±30.81, p = 0.076) and DBP (85.57±12.76 vs 83.32±7.30, p = 0.192) of type 2 diabetic and the apparently healthy hypogonadal men. With respect to the LH levels, no significant difference was observed between type 2 diabetic and the apparently healthy hypogonadal men (5.80±3.90 vs 5.80±4.65, p = 0.996). The healthy hypogonadal men were significantly different from the type 2 diabetic hypogonadal men with reference to FBG (10.75±6.21 vs 5.82±0.81, p<0.001), HbA1c (8.06±2.68 vs 4. 87±0.61, p = <0.001) and FSH (7.61±5.16 vs 10.62±5.33, p = 0.003) level (Table 3).

Table 3. Clinical and hormonal parameters of type 2 diabetic and healthy hypogonadal men.

Parameters	Type 2 Diabetics	Healthy controls	95% CI	P value
Age (yrs)	57.48±9.62	56.92±9.94	-3.067–4.188	0.761
BMI (Kg/m²)	22.94±3.98	24.18±3.92	-2.732–0.242	0.099
SBP (mmHg)	144.42±23.39	134.50±30.81	-1.088–20.937	0.076
DBP (mmHg)	85.57±12.76	83.32±7.30	-10146-5.646	0.192
FBG (mmol/L)	10.75±6.21	5.82±0.81	3.707–6.153	<0.001*
HbA1C (%)	8.06±2.68	4. 87±0.61	2.636–3.738	<0.001*
FSH (mIu/ml)	7.61±5.16	10.62±5.33	-4.950-(-1.060)	0.003*
LH (mIu/ml)	6.31±3.95	7.09±2.82	-1.968–0.401	0.192

Open in a new tab

Binary and multivariable logistic regression about determinants of hypogonadism among the study participants

In both the bivariate and multivariate logistic regression analyses, BMI, smoking and leisure time activity (sedentary lifestyle) were associated with hypogonadism in the study population. The odds of having hypogonadism was lower in the men with normal weight and overweight with their underweight counterparts (AOR = 0.33, 95% CI; 0.12–0.96, p = 0.042) and (AOR = 0.29, 95% CI; 0.10–0.84, p = 0.023) respectively. Also, the odds of suffering from hypogonadism was lower in non-smokers compared with smokers (AOR: 0.16, 95% CI; 0.05–0.58, p = 0.005). Participants who were engaged in light (AOR: 0.29, 95% CI; 0.14–0.61, p = 0.001), moderate (AOR: 0.26, 95% CI; 0.13–0.54, p<0.001) and heavy (AOR: 0.25, 95% CI; 0.10–0.67, p = 0.006) leisure time activities had lower odds hypogonadal compared to those engaged in sedentary living (Table 4).

Table 4. Binary and multivariate logistic regression of sociodemographic, clinical and lifestyle factors associated of hypogonadism in the study participants.

Characteristics	HYPOGONADISM		Unadjusted OR[95% CI]	P value	Adjusted OR[95% CI]	P value
	Yes	No
	N = 144	N = 156
Age (years)
41–50	38(43.2)	50(56.8)	1		1
51–60	42(54.5)	35(45.5)	1.58[0.85–2.92]	0.146	1.80[0.90–3.90]	0.094
61–70	64(47.4)	71(52.6)	1.89[0.69–2.04]	0.536	1.20[0.57,2.40]	0.666
BMI (kg/m ² )
Underweight	17(68.0)	8(32.0)	1		1
Normal weight	84(49.4)	86(50.6)	0.46[0.19–1.12]	0.088	0.33[0.12–0.96]	0.042*
Overweight	36(39.6)	55(60.4)	0.31[0.12–1.79]	0.014*	0.29[0.10–0.84]	0.023*
Obese	7(50.0)	7(50.0)	0.47[0.12–1.80]	0.271	0.63[0.12,3.21]	0.575
Occupation
Unemployed	24(40.0)	36(60.0)	1		1
Farming	70(51.9)	65(48.1)	1.62[0.87–2.99]	0.128	2.11[0.90–4.93]	0.086
Trading	33(56.9)	25(43.1)	1.98[0.95–4.12]	0.068	1.93[0.75–4.98]	0.176
Civil Servants	17(36.2)	30(63.8)	0.85[0.39–1.87]	0.686	0.82[0.30–2.21]	0.688
Alcohol consumption
Yes	8(57.1)	6(42.9)	1		1
No	136(47.6)	150(52.4)	0.68[0.43–2.01]	0.485	0.62[0.18–2.16]	0.458
Smoking
Yes	15(78.9)	129(45.9)	1		1
No	4(21.1)	152(54.1)	0.23[0.07,0.70]	0.010*	0.16[0.05–0.58]	0.005*
HRQoL
Poor	20(45.5)	24(54.5)	1		1
Good	124(48.4)	132(51.6)	1.10[0.59–2.14]	0.715	1.30[0.63–2.68]	0.342
Leisure Time Activity
Sedentary	49(65.3)	26(34.7)	1		1
Light	40(43.5)	52(56.5)	0.41[0.22–0.78]	0.005*	0.29[0.14–0.61]	0.001*
Moderate	43(41.7)	60(58.3)	0.38[0.21–0.70]	0.002*	0.26[0.13–0.54]	<0.001*
Heavy	12(40.0)	18(60.0)	0.35[0.15–0.85]	0.019*	0.25[0.10–0.67]	0.006*
Erectile function status
No ED	15(34.9)	28(65.1)	1
ED	129(50.2)	128(48.9)	1.88[0.96–3.69]	0.066	1.30[0.60–2.78]	0.517

Open in a new tab

Body Mass Index (BMI), Health-related Quality of Life (HRQoL), Erectile Dysfunction (ED).

Discussion

The testosterone hormone has a major impact on men’s overall health and well-being. This hospital-based case-control study sort to ascertain the prevalence and determinants of low testosterone levels in Type 2 diabetes mellitus Ghanaian men compared to non-diabetic controls. The findings revealed that, the mean age of diabetic men in this sample was not substantially different from that of non-diabetic men. The main occupation of the inhabitants of this district is farming, therefore it was not surprising that most of the study participants were farmers. Compared to the type 2 diabetic men, the healthy men recorded the highest number of smokers and alcohol consumers. It is likely that health education provided to diabetic patients during their routine clinics encouraged some to quit smoking and drinking excessively as part of lifestyle modification. More so, the use of questionnaires to assess smoking and alcohol consumption status may have a social desirability issue diminishing response rate. The majority of the diabetic men had a good quality of life compared with healthy controls. It is plausible that the diabetic patients are educated on the implication of worrying and overthinking on blood glucose control, hence the observed difference. A sedentary lifestyle was observed more in the healthy group compared with the diabetics. This is probably because of sedentary lifestyle modification in most diabetic men due to their condition.

Erectile dysfunction rate was quite high in our study subjects irrespective of their diabetic status and it seems normal at this age group. According to a recent analysis on the prevalence of sexual dysfunction the prevalence of ED was 1%–10% in men younger than 40 years, 2%–9% among men between 40 and 49 years, and it increased to 20%–40% among men between 60–69 years, reaching the highest rate in men older than 70 years (50%–100%) [19]. In the Massachusetts Male Aging Study, diabetic men showed a threefold probability of having ED than men without diabetes; moreover, the age-adjusted risk of ED was doubled in diabetic men compared with those without diabetes [20]. Similar erectile dysfunction rates were also found in France, where 39% of men aged 18 to 70 reported erectile dysfunction [21]. Another report by Thai Erectile Dysfunction Epidemiological Study Group (TEDES) among men aged 40 to 70 revealed an erectile dysfunction prevalence of 37.5% [22]. The findings of this study defining the age group for erectile dysfunction does not rule out ED at early or late stage, therefore categorizing our age group around 40–70 years could not change already known facts the most important factor is the stage of the diabetes. Among the diabetic patients, as age increases and/ or the condition progresses, the risk of developing peripheral neuropathy, hypertension, and impotency would also elevate, which might be the reason for an increased odds of ED.

The findings of the study depicted that the T2DM cohort had a lower BMI than the control cohort. Even though the average BMI of the diabetic men was significantly lower than the healthy men, both were within the normal range. This contradicts the results of [17] that reported that males with diabetes have a higher average BMI than their non-diabetic counterparts. In the pathogenesis of T2DM, lower body mass index (BMI) is consistently associated with reduced type 2 diabetes risk, among people with varied family history, genetic risk factors and weight, while in established T2DM patients weight loss has been shown to meliorate glycaemic control, with severe calorie restraint even reversing the progression of T2DM [23, 24]. The mechanisms for this BMI paradox are not fully understood, but proposed explanations include T2DM individuals lose weight and become frail as a result of underlying illnesses that cause wasting. A study by Peyrot et al. [25], into possible psychological barriers to diabetes care, also found that many participants with T2DM felt very anxious and ashamed about their weight and thus reducing their weight reduces their experience of weight stigma.

Another possible explanation is the genetic predisposition in T2DM patients. According to Habbu et al. [26], more South Asians developed T2DM at BMI below 30 kg/m² (38%) than White Europeans (26%) and African-Caribbeans (29%). This suggest a possible low BMI among T2DM patients in our study subjects. Lastly, life style interventions that target diets and weight-loss have shown demonstrable benefit for reducing the risk of type II diabetes in high-risk and pre-diabetic individuals but have not been well-studied in people at lower risk of diabetes. These findings suggest that all individuals can substantially reduce their type 2 diabetes risk through weight loss, and support the broad deployment of weight loss interventions to individuals at all levels of diabetes risk as a public health measure [24]. In our present study since our diabetic cohorts visit the clinic regularly and visit the dietician, there might be measures going on to help reduce the risk of the infection, which might not be seen in the control cohort who might be moving around freely without any restrictions on diet. There was a proportional significant difference between diabetic and non-diabetic subjects for normal weight and overweight. According to Hu et al. [27], overweight is the single most significant defining factor of type 2 diabetes; therefore, it was not shocking to see that more diabetic men were overweight and obese than healthy men.

The mean systolic and diastolic blood pressures were significantly higher in diabetic men. Previous studies have asserted that the most adverse outcome of type 2 diabetes mellitus is hypertension because of the complications like diabetic nephropathy, increased exchangeable sodium, insulin resistance and peripheral vascular resistance associated with the disease [28, 29]. Other previous studies have also shown a significant mean difference in body mass index, systolic and diastolic blood pressures and fasting blood glucose between diabetic men and control groups [30, 31]. Also, a significant elevation of FBS and HbA1c levels was identified in the diabetic group compared to the non-diabetics. The elevated FBS and poor glycaemic control have been found to be directly proportional to the severity of the diabetes mellitus. The increasing FBS level and poor glycaemic control in the diabetic group were also in agreement with many other research findings [1, 18, 32].

The biochemical findings of this study showed a highly significant reduction in FSH, LH and testosterone levels were observed in the diabetic group compared to the healthy group. This agrees with the finding of Dhindsa et al. [33], which stated a significantly lower FSH and LH concentrations in the diabetic group compared with the controls. This finding also agrees in part with a study conducted by Hussein & Al-qaisi [1], except that their study reported an increased LH level in diabetic group. The diminished gonadotropin secretion in our diabetic subjects might have resulted in insufficient testicular stimulation, hence a reduction in testosterone secretion. Low testosterone levels in the diabetic men may interfere with potency, spermatogenesis and consequently fertility. Our findings showed a significant inverse relationship between low testosterone and FBS and HbA1c. Glycaemia is known to affect Leydig cell function directly causing primary hypogonadism and therefore the association between FBS, HbA1c and reduced total testosterone concentration might be an adverse effect of glycaemia on the testicular microvasculature. The low testosterone levels observed could also be a result of glucose not reaching the cells due to insulin insensitivity, to provide enough energy for the various metabolic processes involved in maintaining testosterone levels [9].

The study depicted that, most of our study participants had low testosterone level. Most of the study participants were at the age group of 40 to 70 years. Studies have shown that mean testicular volume and gonadal function diminishes at this ages. The mean testicular volume tends to increase between 11 and 30 years of age, remains constant between 30 and 60 years of age, and decreases gradually every year after age 60 [34]. Few data on hypogonadism in aging men are available because of the deficiency of evidence regarding the exact criteria for distinguishing testosterone deficiency in older men who do not have pathological hypogonadism [35–37]. The Massachusetts Male Aging Study, using both total testosterone and calculated free testosterone, gave crude prevalence estimates for hypogonadism in men from age 40 to 69 years, ranging at baseline from 6.0 to 12.3% [38]. This is in accordance with the results of this study. Mahmoud et al. [39], found the mean testicular volume in men over 75 years to be 31% less than in men between 18 and 40 years of age. This difference is associated with significantly higher mean serum levels of gonadotropins and lower serum free testosterone. Interestingly, when the incidence of hypogonadism was determined by decades, nearly all of the categories of illness were more prevalent in men aged 50–70 years [40], which is consistent with our study.

This study showed that hypogonadism is a common defect in type 2 diabetic men, affecting more than half of the study group, irrespective of their baseline clinical, lifestyle or demographic characteristics. Drugs commonly implicated to induce mild to moderate reduction in serum testosterone levels include B blocker antihypertensive and anticholesterols (statins) which are mostly prescribed for the management of hypertension in T2DM and hypertension co-morbidity [41]. The high prevalence of hypogonadism in the study population raises important issues about its possible consequences the sexual, reproductive and general health (libido, erectile dysfunction, body musculature, abdominal adiposity, bone density, mood, and cognition) of our study population. The Endocrine Society has recommended routine examination and replacement therapy for diabetic patients [42]. However, most facilities in Ghana have not adopted it because of limited resources and cost-ineffectiveness of screening all men for hypogonadism.

A study conducted in Ghana reported a hypogonadism prevalence of 35.2% in men with type 2 diabetes [5]. Unlike this previous study which was conducted in urban setting and a teaching hospital, our study was carried out in a peri-urban setting and district hospital. Other previous studies have shown a prevalence of 30–80% in men with type 2 diabetes [43–45]. The disparities in prevalence could be attributed to the difference in population examined, the definition used for the diagnosis of hypogonadism and the sample size.

Clinical and hormonal parameters of type 2 diabetic and healthy hypogonadal men were again determined. The mean age, BMI, SBP, DBP and LH between the type 2 diabetic and the apparently healthy hypogonadal men were not significantly different. This finding did not agree with a study that have linked decreasing testosterone levels with aging even in healthy men [11]. The multivariate analysis from our study indicated that BMI, smoking and leisure time activity (sedentary lifestyle) were associated with hypogonadism in the study population. Most cross-sectional studies have shown a positive association between smoking and total or free testosterone levels [46, 47]. Also, some studies have shown a significant association between BMI and hypogonadism [5, 48, 49], while another had reported no relationship between testosterone and BMI [50]. The lack of physical exercise activity contributes to lowering down the testosterone hormone level and indeed beside the effect of obesity [9].

There are few limitations in the study. Firstly, this was a case-control design, which made it impossible to determine whether diabetes preceded or followed the decline in hormone levels. The study did not measure Estradiol (E2) to ascertain any trend because it has been shown that low testosterone levels in diabetes could also be as a result of their increased conversion to E2. The study was also limited by the advanced age of the participants (41–70 years), hence the high prevalence of hypogonadism may have been masked by the age bracket of the study participants. To help address this limitation, we recommend future studies to consider participants below 40 years of age. In the face of these limitations, this study gives significant data for the occurrence and predictors of hypogonadism among Ghanaian men with T2D in the district.

Conclusion

The study recorded a worrying prevalence of hypogonadism even among the healthy control group but with Type 2 diabetic men having a high incidence of hypogonadism. This study also demonstrates that FSH and LH concentrations are certainly lower in a relatively large number of the males with type II diabetes compared with the healthy men. Body Mass Index, smoking and leisure time activity (sedentary lifestyle) were associated with hypogonadism in the study population. Given a large number of individuals with diabetes worldwide, the high prevalence of hypogonadism in type 2 diabetes raises important issues about its possible consequences on the sexual, reproductive and general health of our study population. A further study is recommended to carry out to holistically assess the prevalence of gonadal deficiencies in subjects with prediabetes patients aged between 20–40 years at the district hospital.

Supporting information

S1 Data. All data and related metadata underlying the findings reported are provided as part of the submitted article.

(RAR)

Click here for additional data file.^{(11.6KB, rar)}

S1 Checklist. Checklist of items that should be included in reports of case-control studies.

*Give information separately for cases and controls in case-control studies, NA = Not Applicable.

(DOCX)

Click here for additional data file.^{(32KB, docx)}

Acknowledgments

We are grateful for the immense contributions of the staff of Nkenkaasu District Hospital and Wenchi Methodist Hospital Laboratories, not forgetting our participants.

Data Availability

All data are in the manuscript and/or Supporting information files.

Funding Statement

The author(s) received no specific funding for this work.

References

1.Hussein Z, Al-qaisi J. Effect of Diabetes mellitus Type 2 on Pituitary Gland Hormones (FSH, LH) in Men and Women in Iraq. 2012;15(3). [Google Scholar]
2.Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. doi: 10.1016/j.diabres.2009.10.007 [DOI] [PubMed] [Google Scholar]
3.Beran D, Yudkin JS. Diabetes care in sub-Saharan Africa. 2006;1689–95. [DOI] [PubMed] [Google Scholar]
4.Amoah AGB, Owusu SK, Adjei S. Diabetes in Ghana: a community based prevalence study in Greater Accra. 2002;56:197–205. [DOI] [PubMed] [Google Scholar]
5.Asare-Anane H, Ofori EK, Yeboah FA, Tagoe EA, Bani SB, Bawah AT, et al. Primary hypogonadism in Ghanaian men with type 2 diabetes mellitus. Cell. 2013;2(5):310–5. [Google Scholar]
6.Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35. doi: 10.1056/NEJMoa0911101 [DOI] [PubMed] [Google Scholar]
7.Swerdloff R, Wang C. Testosterone treatment of older men—why are controversies created? Oxford University Press; 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Basaria S. Male hypogonadism. Lancet. 2014;383(9924):1250–63. doi: 10.1016/S0140-6736(13)61126-5 [DOI] [PubMed] [Google Scholar]
9.Mohieldin JM, Sc M, Babiker N, Ph D, Abdalla OM, Ph D. Effect of Type2 Diabetes Mellitus on Sudanese Male Fertility. 2016;4:2216–23. [Google Scholar]
10.Beatrice AM, Ray S. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. 2014;481–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Ugwu T, Ezeani I, Onung S, Kolawole B, Ikem R. Predictors of Erectile Dysfunction in Men with Type 2 Diabetes Mellitus Referred to a Tertiary Healthcare Centre. 2016;2016. [Google Scholar]
12.Offinso north district GSS. Ghana statistical service, 2010 population and housing Census, District Analytical Report, Offinso North District [Internet]. 2014. http://www2.statsghana.gov.gh/docfiles/2010_District_Report/Ashanti/OffinsoNorth.pdf
13.Ephraim RKD, Awuku YA, Adu P, Ampomah LTW, Adoba P, Panford S, et al. High risk of coagulopathy among Type-2 Diabetes Mellitus clients at a municipal hospital in Ghana. Ghana Med J. 2017;51(3):101–7. doi: 10.4314/gmj.v51i3.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Nkansah C, Addai-Mensah O, Mensah K, Owusu M, Ephraim RKD, Adu P, et al. Plasminogen Activator Inhibitor-1 in poorly controlled vs well controlled Type-2 Diabetes Mellitus patients: A case-control study in a district hospital in Ghana. PLoS One. 2021;16(4):e0250090. doi: 10.1371/journal.pone.0250090 [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Larsson CA, Krøll L, Bennet L, Gullberg B, Råstam L, Lindblad U. Leisure time and occupational physical activity in relation to obesity and insulin resistance: a population-based study from the Skaraborg Project in Sweden. Metabolism. 2012;61(4):590–8. doi: 10.1016/j.metabol.2011.09.010 [DOI] [PubMed] [Google Scholar]
16.Serwaa D, Bello FA, Osungbade KO, Nkansah C. Prevalence and Determinant of Erectile Dysfunction in Type II Diabetes Mellitus and Healthy Men. SciMedicine J. 2021;3(1):23–34. [Google Scholar]
17.Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Bangkok). 2005;27(2):156–64. doi: 10.1093/pubmed/fdi025 [DOI] [PubMed] [Google Scholar]
18.Rahmat RA, Sultan AS. THE EFFECTS OF TYPE 2 DIABETIC MELLITUS ON THE LEVELS OF TESTOSTERONE, ESTRADIOL, GONADOTROPINS, AND RETINOL BINDING PROTEIN 4. 2017;7(2):404–10. [Google Scholar]
19.Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7(4):1598–607. doi: 10.1111/j.1743-6109.2010.01778.x [DOI] [PubMed] [Google Scholar]
20.Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKINLAY JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460–3. [PubMed] [Google Scholar]
21.Ansong KS, Lewis C, Jenkins P, Bell J. Epidemiology of erectile dysfunction: a community-based study in rural New York State. Ann Epidemiol. 2000;10(5):293–6. doi: 10.1016/s1047-2797(00)00050-8 [DOI] [PubMed] [Google Scholar]
22.Erectile T. An epidemiological study of erectile dysfunction in Thailand (Part 1: Prevalence). J Med Assoc Thail. 2000;83(8):872. [PubMed] [Google Scholar]
23.Wilding JPH. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68(6):682–91. doi: 10.1111/ijcp.12384 [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Wainberg M, Mahajan A, Kundaje A, McCarthy MI, Ingelsson E, Sinnott-Armstrong N, et al. Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: a Mendelian randomization study. PLoS Med. 2019;16(12):e1002982. doi: 10.1371/journal.pmed.1002982 [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Peyrot M, McMurry JF Jr, Kruger DF. A biopsychosocial model of glycemic control in diabetes: stress, coping and regimen adherence. J Health Soc Behav. 1999;141–58. [PubMed] [Google Scholar]
26.Habbu A, Lakkis NM, Dokainish H. The obesity paradox: fact or fiction? Am J Cardiol. 2006;98(7):944–8. doi: 10.1016/j.amjcard.2006.04.039 [DOI] [PubMed] [Google Scholar]
27.Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790–7. doi: 10.1056/NEJMoa010492 [DOI] [PubMed] [Google Scholar]
28.Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. Jama. 2010;304(1):61–8. doi: 10.1001/jama.2010.884 [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Snow V, Weiss KB, Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med. 2003;138(7):587–92. doi: 10.7326/0003-4819-138-7-200304010-00017 [DOI] [PubMed] [Google Scholar]
30.Asare-Anane H Ofori T et al. Obesity and Testosterone Levels in Ghanaian Men With Type 2 Diabetes. Clin Diabetes [Internet]. 2014;32(2):61–5. Available from: http://clinical.diabetesjournals.org/cgi/doi/10.2337/diaclin.32.2.61 [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Ferrini RL, Barrett-connor E. Sex Hormones and Age: A Cross-sectional Study of Testosterone and Estradioi and Their Bioavailable Fractions in Community-dwelling Men. 2018;147(8):750–4. [DOI] [PubMed] [Google Scholar]
32.Njølstad PR, Sagen JV, Bjørkhaug L, Odili S, Shehadeh N, Bakry D, et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes. 2003;52(11):2854–60. doi: 10.2337/diabetes.52.11.2854 [DOI] [PubMed] [Google Scholar]
33.Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S. Hypogonadotrophic hypogonadism in type 2 diabetes. 2009;5538. [DOI] [PubMed] [Google Scholar]
34.Yang H, Chryssikos T, Houseni M, Alzeair S, Sansovini M, Iruvuri S, et al. The effects of aging on testicular volume and glucose metabolism: an investigation with ultrasonography and FDG-PET. Mol imaging Biol. 2011;13(2):391–8. doi: 10.1007/s11307-010-0341-x [DOI] [PubMed] [Google Scholar]
35.McKinlay JB, Travison TG, Araujo AB, Kupelian V. Male menopause-time for a decent burial? Menopause. 2007;14(6):973–5. doi: 10.1097/gme.0b013e31815708ee [DOI] [PubMed] [Google Scholar]
36.Wu FCW. Guideline for male testosterone therapy: a European perspective. J Clin Endocrinol Metab. 2007;92(2):418–9. doi: 10.1210/jc.2006-2799 [DOI] [PubMed] [Google Scholar]
37.Liverman CT, Blazer DG. Testosterone and health outcomes. In: Testosterone and Aging: Clinical Research Directions. National Academies Press (US); 2004. [PubMed] [Google Scholar]
38.Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89(12):5920–6. doi: 10.1210/jc.2003-031719 [DOI] [PubMed] [Google Scholar]
39.Mahmoud AM, Goemaere S, El-Garem Y, Van Pottelbergh I, Comhaire FH, Kaufman JM. Testicular volume in relation to hormonal indices of gonadal function in community-dwelling elderly men. J Clin Endocrinol Metab. 2003;88(1):179–84. doi: 10.1210/jc.2002-020408 [DOI] [PubMed] [Google Scholar]
40.Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol. 2004;171(6):2341–5. doi: 10.1097/01.ju.0000125198.32936.38 [DOI] [PubMed] [Google Scholar]
41.Schooling CM, Yeung SLA, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11(1):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5–15. doi: 10.3109/13685538.2015.1004049 [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005;63(3):239–50. doi: 10.1111/j.1365-2265.2005.02299.x [DOI] [PubMed] [Google Scholar]
44.Hackett G. Type 2 Diabetes and Testosterone Therapy. World J Mens Health. 2019;37(1):31. doi: 10.5534/wjmh.180027 [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros J, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl. 2005;28(3):125–7. doi: 10.1111/j.1365-2605.2005.00553.x [DOI] [PubMed] [Google Scholar]
46.Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Valkonen V-P, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005;90(2):712–9. doi: 10.1210/jc.2004-0970 [DOI] [PubMed] [Google Scholar]
47.Trummer H, Habermann H, Haas J, Pummer K. The impact of cigarette smoking on human semen parameters and hormones. Hum Reprod. 2002;17(6):1554–9. doi: 10.1093/humrep/17.6.1554 [DOI] [PubMed] [Google Scholar]
48.Onahn CE, Meludu SC, Dioka CE, Onuegbu JA. Pattern of male sex hormones in type 2 diabetic patients in Nnewi, South Eastern Nigeria. IOSR-JDMS. 2013;10(4):65–70. [Google Scholar]
49.Saboor Aftab SA, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol (Oxf). 2013;78(3):330–7. doi: 10.1111/cen.12092 [DOI] [PubMed] [Google Scholar]
50.Tripathy D, Dhindsa S, Garg R, Khaishagi A, Syed T, Dandona P. Hypogonadotropic hypogonadism in erectile dysfunction associated with type 2 diabetes mellitus: a common defect? Metab Syndr Relat Disord. 2003;1(1):75–80. doi: 10.1089/154041903321648270 [DOI] [PubMed] [Google Scholar]

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0000052.r001

Decision Letter 0

Palash Chandra Banik, Julia Robinson

6 Aug 2021

PGPH-D-21-00300

Prevalence and determinants of low testosterone levels in Type II diabetes mellitus men; a case-control study in a district hospital in Ghana

PLOS Global Public Health

Dear Dr. Serwaa,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please consider incorporating the comments of all reviewers.

Please submit your revised manuscript by 05 September, 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Palash Chandra Banik, MPhil

Academic Editor

PLOS Global Public Health

Journal Requirements:

Additional Editor Comments (if provided):

- Please ensure the language editing throughout the manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Authors try to find the prevalence and detrimental effect of testosterone levels in type 2 diabetes patients by case control study population. Previously, many studies were reported the increased testosterone levels in type 2 diabetes patients like "Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis"

however, the present study findings are specific to the ghana city. The provided information is not a new information and novelty of the study was not observed.

Few minor corrections:

Type II diabetes need to be replaced with type 2 diabetes mellites.

articles needs to be written well Like, line 25 The should be capital

Line 374 it is written that cross sectional study and before it is written as case control study. Need a clarity on this.

Table 3 Odd ratio is missing.

Reviewer #2: Dr. Serwaa and colleagues present a detailed case control study of 300 men with type 2 diabetes mellitus and average normal weight for low testosterone in a district hospital within a peri-urban setting, finding significant associations in this populations as shown in a prior urban setting in Ghana. Their results contribute to the literature associating type 2 diabetes and dysglycemia with male hypogonadism, in this case in a peri-urban setting of Nkenkaasu Hospital in Nkenkaasu, Ghana, West Africa in a distinct population from prior studies that contributes to the global understanding of male hypogonadism prevalence. A particular finding of interest is that both their case and control cohorts of moderate size where of normal weight on average, with their diabetes group having suboptimal glycemic control by A1c (8.06) and lower BMI (23.05) than their control group. Strengths also include measurement of pituitary hormones LH and FSH which are lower in the diabetes group, suggesting a relative secondary hypogonadism compared to the control cohort and consistent with hypogonadism occurring in type 2 diabetes. The results presented are complete, the statistical analysis is rigorous and the study was conducted following Declaration of Helsinki ethical principles. Figures 1 and 2 are particularly informative as the convey the variation in testosterone levels in relation to fasting blood glucose and HbA1c. The discussion is nicely written and cites relevant literature including articles documenting similar associations in the Ghanian population as well as the Endocrine Society guidelines as applied in this population. The authors acknowledge limitations of the study including difficulty measuring testosterone in this community due to lack of treatment access, and lack of estradiol measurement.

--Major Issues

*Title: The current title is worded awkwardly and should use person-first language such as “"Prevalence and determinants of low testosterone levels in men with Type II diabetes mellitus; a case-control study in a district hospital in Ghana"

*Assay: The methodological description of the assay AccuDiag Testosterone Assay Kit suggests using a total testosterone measurement, but the authors later refer to free testosterone in the results section. Could the authors clarify if they measured total, free or both testosterone levels? Male hypogonadism in insulin resistance partially involves a decrease in SHBG lowering total testosterone levels, but preserving intact free testosterone levels. This distinction is important as the ELISA assay is different than the commonly accepted LC-MS assays used in other parts of the world that report both free and total testosterone levels.

*Results – One of the more interesting findings of the study is that the diabetes cohort had a lower BMI than the control cohort. Could the authors comment on reasons as to why this might be a difference? Could it be attributed to stage of type 2 diabetes, poor control and subsequent glucosuria, or other factors?

*Results – Dysglycemia occurs in a spectrum, and the authors likely observed similar gonadal deficiencies in subjects with prediabetes as part of clinical care. Could the authors comment on how the observed association would be affected by prediabetes in their population, or as a future study?

*Reporting standards – As a reviewer I would ask the authors to complete the STROBE statement checklist for ease of review (https://www.strobe-statement.org/index.php?id=strobe-home). Most of the elements are included in the document, but the checklist would simplify review and compliance checking. Unfortunately I was not able to review the supplemental material in the RAR or data.sav file provided.

--Minor Issues

*I would suggest organizing the manuscript with the text first and tables at the end per usual manuscript submission guidelines.

*There are minor grammatical spelling errors that can be corrected with editorial assistance. The list below is not exhaustive:

Page 13, lines 216-217: Sentence should be corrected to “The body mass index (BMI) of the healthy controls was significantly higher than...”

Page 15, line 258: Sentence should start with “The distribution…"

Page 22: Line 326: Sentence should be corrected to “Author SD conceived the study.”

Reviewer #3: Definitely this is a great study and the authors hard work should be paid off. Worldwide such type of study is really limited. But the population age is a matter here. Normally within aging the gonads normally begin to do less performance. At this study, population age ranges from 40 - 70 years. Naturally, gonadal function will be decreased. But the main outcome of the study is all right, healthy individuals showed normal testosterones level than the diabetic population. If the population age is limited to 18 from 50, then more scientific evidence can be created which obviously can help on reproductive and over all life outcome. However, this study will also generate evidence. But, i found several lines and write up as out of the main flaws. Here are my comments-

INTRODUCTION:

1. Line no-61: Why loss of memory, depression, lack of concentration will come first over riding the main affects of hypogonadism? I would like to request the author to organize the line accordingly with proper citation.

2. What does the author mean by " Physical decline". Please clarify

3. Type-2 DM is written differently in all over the manuscript. I would request to use one uniform pattern.

STUDY PARTICIPANTS:

1. Cut off values for fasting blood sugar and HBA1c is adopted from where? Any reference, then author should mention it. Because different guidelines use different cut off values.

2. Study participant selection criteria should be more clear.

BODY MASS INDEX- Authors have categorized according to WHO BMI Category? But why no citation or acknowledgement?

BP MEASUREMENT- Line no 124 and whole procedure of BP measurement were done maintain a standard procedure. So, why no citation or acknowledgement?

BLOOD SAMPLE COLLECTION- This procedure is also done maintaining standard protocol. Is it? Clear writing and proper citation is very necessary here.

LABORATORY ASSAY- Are the whole cut off/ normal values are taken from standard guideline? Nothing is clear over there. If yes, then acknowledgement is required.

RESULS:

1. Most of the study participants were at the age group of 40 to 70 years. Normally gonadal function diminishes at this ages. Although a clear explanation is given on the discussion part, but i found it as not enough. It should be more clarified along with some evidences from published studies.

2. Erectile dysfunction rate is quite high and it seems normal at this age group. But the normal individual is also fall into that category. A clear explanation on this finding is very necessary to make the statement reader palatable.

DISCUSSION:

This part is quite good and have made many things clear. But still there are few scope to make it more synchronized with the findings from analysis.

Conclusion:

Few lines were beautifully written. But last portion is quite hazy and it demands re- write maintaining a flaws with the overall study.

ABSTRACT and TITLE: This is quite good and well Witten. But, again the conclusion should be more specified .

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. 2021 Dec 2;1(12):e0000052. doi: 10.1371/journal.pgph.0000052.r002

Author response to Decision Letter 0

5 Sep 2021

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file.^{(26.3KB, docx)}

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0000052.r003

Decision Letter 1

Palash Chandra Banik, Julia Robinson

27 Sep 2021

PGPH-D-21-00300R1

Prevalence and determinants of low testosterone levels in men with Type 2 diabetes mellitus; a case-control study in a district hospital in Ghana.

PLOS Global Public Health

Dear Dr. Serwaa,

==============================

Dear Authors, Kindly address all the points raised by the reviewers.

==============================

Please submit your revised manuscript by 15 October, 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Palash Chandra Banik, MPhil

Academic Editor

PLOS Global Public Health

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

Dear Authors

Please address the reviewers comments accordingly.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

6. Review Comments to the Author

Reviewer #1: authors clarified and modified according to our comments

Reviewer #2: Comments to the author:

Dr. Serwaa and colleagues present a detailed case control study of 300 men with type 2 diabetes mellitus and average normal weight for low testosterone in a district hospital within a peri-urban setting, finding significant associations in this populations as shown in a prior urban setting in Ghana. Their results contribute to the literature associating type 2 diabetes and dysglycemia with male hypogonadism, in this case in a peri-urban setting of Nkenkaasu Hospital in Nkenkaasu, Ghana, West Africa in a distinct population from prior studies that contributes to the global understanding of male hypogonadism prevalence. A particular finding of interest is that both their case and control cohorts of moderate size were of normal weight on average, with their diabetes group having suboptimal glycemic control by A1c (8.06) and lower BMI (23.05) than their control group. Strengths also include measurement of pituitary hormones LH and FSH which are lower in the diabetes group, suggesting a relative secondary hypogonadism compared to the control cohort and consistent with hypogonadism occurring in type 2 diabetes. The results presented are complete, the statistical analysis is rigorous and the study was conducted following Declaration of Helsinki ethical principles. Figures 1 and 2 are particularly informative as the convey the variation in testosterone levels in relation to fasting blood glucose and HbA1c. The discussion is nicely written and cites relevant literature including articles documenting similar associations in the Ghanian population as well as the Endocrine Society guidelines as applied in this population. The authors acknowledge limitations of the study including difficulty measuring testosterone in this community due to lack of treatment access, and lack of estradiol measurement.

I appreciate the inclusion of the STROBE checklist for case-control studies, and have no additional changes to suggest to the authors.

Reviewer #3: Authors hard work and determination is praiseworthy. They have addresses all the comments raised by the reviewers and it has shaped the manuscript into a more attractive form. But still i have noticed few things are not on that standard. These comments are below

# Objectives and rationale of the study is still hazy. Last part of introduction is not well written and is giving a discrete essence.

#Sample size is less, so it is really difficult to address the title as prevalence study. It is only a proportion from small samples.

#Age group of the study may create a dilemma.

#Despite of having standard cot of values from ADA, WHO authors have used so many secondary references. I personally not in a favor to use this.

#Could not co-relate the line no 130 with the citation number 14.

#Line 193-195 demands an acknowledgement, but this is absent there i see.

#Discussion and conclusion is well in re-written form

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Jose O. Aleman

Reviewer #3: No

**********

PLOS Glob Public Health. 2021 Dec 2;1(12):e0000052. doi: 10.1371/journal.pgph.0000052.r004

Author response to Decision Letter 1

3 Oct 2021

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file.^{(15.7KB, docx)}

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0000052.r005

Decision Letter 2

Palash Chandra Banik, Julia Robinson

18 Oct 2021

Prevalence and determinants of low testosterone levels in men with Type 2 diabetes mellitus; a case-control study in a district hospital in Ghana.

PGPH-D-21-00300R2

Dear Dr. Serwaa,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at https://www.editorialmanager.com/pgph/ click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Kind regards,

Palash Chandra Banik, MPhil

Academic Editor

PLOS Global Public Health

Additional Editor Comments (optional):

Dear Authors, Please reply the reviewer comments if any.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #3: All comments have been addressed

**********

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #3: Yes

**********

6. Review Comments to the Author

Reviewer #3: Authors hard work is praiseworthy. All comments are addressed and the new form of manuscript is better understandable.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: Yes: Fardina Rahman Omi

**********

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Data. All data and related metadata underlying the findings reported are provided as part of the submitted article.

(RAR)

Click here for additional data file.^{(11.6KB, rar)}

S1 Checklist. Checklist of items that should be included in reports of case-control studies.

*Give information separately for cases and controls in case-control studies, NA = Not Applicable.

(DOCX)

Click here for additional data file.^{(32KB, docx)}

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file.^{(26.3KB, docx)}

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file.^{(15.7KB, docx)}

Data Availability Statement

All data are in the manuscript and/or Supporting information files.

[pgph.0000052.ref001] 1.Hussein Z, Al-qaisi J. Effect of Diabetes mellitus Type 2 on Pituitary Gland Hormones (FSH, LH) in Men and Women in Iraq. 2012;15(3). [Google Scholar]

[pgph.0000052.ref002] 2.Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. doi: 10.1016/j.diabres.2009.10.007 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref003] 3.Beran D, Yudkin JS. Diabetes care in sub-Saharan Africa. 2006;1689–95. [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref004] 4.Amoah AGB, Owusu SK, Adjei S. Diabetes in Ghana: a community based prevalence study in Greater Accra. 2002;56:197–205. [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref005] 5.Asare-Anane H, Ofori EK, Yeboah FA, Tagoe EA, Bani SB, Bawah AT, et al. Primary hypogonadism in Ghanaian men with type 2 diabetes mellitus. Cell. 2013;2(5):310–5. [Google Scholar]

[pgph.0000052.ref006] 6.Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35. doi: 10.1056/NEJMoa0911101 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref007] 7.Swerdloff R, Wang C. Testosterone treatment of older men—why are controversies created? Oxford University Press; 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref008] 8.Basaria S. Male hypogonadism. Lancet. 2014;383(9924):1250–63. doi: 10.1016/S0140-6736(13)61126-5 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref009] 9.Mohieldin JM, Sc M, Babiker N, Ph D, Abdalla OM, Ph D. Effect of Type2 Diabetes Mellitus on Sudanese Male Fertility. 2016;4:2216–23. [Google Scholar]

[pgph.0000052.ref010] 10.Beatrice AM, Ray S. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. 2014;481–6. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref011] 11.Ugwu T, Ezeani I, Onung S, Kolawole B, Ikem R. Predictors of Erectile Dysfunction in Men with Type 2 Diabetes Mellitus Referred to a Tertiary Healthcare Centre. 2016;2016. [Google Scholar]

[pgph.0000052.ref012] 12.Offinso north district GSS. Ghana statistical service, 2010 population and housing Census, District Analytical Report, Offinso North District [Internet]. 2014. http://www2.statsghana.gov.gh/docfiles/2010_District_Report/Ashanti/OffinsoNorth.pdf

[pgph.0000052.ref013] 13.Ephraim RKD, Awuku YA, Adu P, Ampomah LTW, Adoba P, Panford S, et al. High risk of coagulopathy among Type-2 Diabetes Mellitus clients at a municipal hospital in Ghana. Ghana Med J. 2017;51(3):101–7. doi: 10.4314/gmj.v51i3.2 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref014] 14.Nkansah C, Addai-Mensah O, Mensah K, Owusu M, Ephraim RKD, Adu P, et al. Plasminogen Activator Inhibitor-1 in poorly controlled vs well controlled Type-2 Diabetes Mellitus patients: A case-control study in a district hospital in Ghana. PLoS One. 2021;16(4):e0250090. doi: 10.1371/journal.pone.0250090 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref015] 15.Larsson CA, Krøll L, Bennet L, Gullberg B, Råstam L, Lindblad U. Leisure time and occupational physical activity in relation to obesity and insulin resistance: a population-based study from the Skaraborg Project in Sweden. Metabolism. 2012;61(4):590–8. doi: 10.1016/j.metabol.2011.09.010 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref016] 16.Serwaa D, Bello FA, Osungbade KO, Nkansah C. Prevalence and Determinant of Erectile Dysfunction in Type II Diabetes Mellitus and Healthy Men. SciMedicine J. 2021;3(1):23–34. [Google Scholar]

[pgph.0000052.ref017] 17.Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Bangkok). 2005;27(2):156–64. doi: 10.1093/pubmed/fdi025 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref018] 18.Rahmat RA, Sultan AS. THE EFFECTS OF TYPE 2 DIABETIC MELLITUS ON THE LEVELS OF TESTOSTERONE, ESTRADIOL, GONADOTROPINS, AND RETINOL BINDING PROTEIN 4. 2017;7(2):404–10. [Google Scholar]

[pgph.0000052.ref019] 19.Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7(4):1598–607. doi: 10.1111/j.1743-6109.2010.01778.x [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref020] 20.Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKINLAY JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460–3. [PubMed] [Google Scholar]

[pgph.0000052.ref021] 21.Ansong KS, Lewis C, Jenkins P, Bell J. Epidemiology of erectile dysfunction: a community-based study in rural New York State. Ann Epidemiol. 2000;10(5):293–6. doi: 10.1016/s1047-2797(00)00050-8 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref022] 22.Erectile T. An epidemiological study of erectile dysfunction in Thailand (Part 1: Prevalence). J Med Assoc Thail. 2000;83(8):872. [PubMed] [Google Scholar]

[pgph.0000052.ref023] 23.Wilding JPH. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68(6):682–91. doi: 10.1111/ijcp.12384 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref024] 24.Wainberg M, Mahajan A, Kundaje A, McCarthy MI, Ingelsson E, Sinnott-Armstrong N, et al. Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: a Mendelian randomization study. PLoS Med. 2019;16(12):e1002982. doi: 10.1371/journal.pmed.1002982 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref025] 25.Peyrot M, McMurry JF Jr, Kruger DF. A biopsychosocial model of glycemic control in diabetes: stress, coping and regimen adherence. J Health Soc Behav. 1999;141–58. [PubMed] [Google Scholar]

[pgph.0000052.ref026] 26.Habbu A, Lakkis NM, Dokainish H. The obesity paradox: fact or fiction? Am J Cardiol. 2006;98(7):944–8. doi: 10.1016/j.amjcard.2006.04.039 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref027] 27.Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790–7. doi: 10.1056/NEJMoa010492 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref028] 28.Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. Jama. 2010;304(1):61–8. doi: 10.1001/jama.2010.884 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref029] 29.Snow V, Weiss KB, Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med. 2003;138(7):587–92. doi: 10.7326/0003-4819-138-7-200304010-00017 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref030] 30.Asare-Anane H Ofori T et al. Obesity and Testosterone Levels in Ghanaian Men With Type 2 Diabetes. Clin Diabetes [Internet]. 2014;32(2):61–5. Available from: http://clinical.diabetesjournals.org/cgi/doi/10.2337/diaclin.32.2.61 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref031] 31.Ferrini RL, Barrett-connor E. Sex Hormones and Age: A Cross-sectional Study of Testosterone and Estradioi and Their Bioavailable Fractions in Community-dwelling Men. 2018;147(8):750–4. [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref032] 32.Njølstad PR, Sagen JV, Bjørkhaug L, Odili S, Shehadeh N, Bakry D, et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes. 2003;52(11):2854–60. doi: 10.2337/diabetes.52.11.2854 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref033] 33.Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S. Hypogonadotrophic hypogonadism in type 2 diabetes. 2009;5538. [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref034] 34.Yang H, Chryssikos T, Houseni M, Alzeair S, Sansovini M, Iruvuri S, et al. The effects of aging on testicular volume and glucose metabolism: an investigation with ultrasonography and FDG-PET. Mol imaging Biol. 2011;13(2):391–8. doi: 10.1007/s11307-010-0341-x [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref035] 35.McKinlay JB, Travison TG, Araujo AB, Kupelian V. Male menopause-time for a decent burial? Menopause. 2007;14(6):973–5. doi: 10.1097/gme.0b013e31815708ee [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref036] 36.Wu FCW. Guideline for male testosterone therapy: a European perspective. J Clin Endocrinol Metab. 2007;92(2):418–9. doi: 10.1210/jc.2006-2799 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref037] 37.Liverman CT, Blazer DG. Testosterone and health outcomes. In: Testosterone and Aging: Clinical Research Directions. National Academies Press (US); 2004. [PubMed] [Google Scholar]

[pgph.0000052.ref038] 38.Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89(12):5920–6. doi: 10.1210/jc.2003-031719 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref039] 39.Mahmoud AM, Goemaere S, El-Garem Y, Van Pottelbergh I, Comhaire FH, Kaufman JM. Testicular volume in relation to hormonal indices of gonadal function in community-dwelling elderly men. J Clin Endocrinol Metab. 2003;88(1):179–84. doi: 10.1210/jc.2002-020408 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref040] 40.Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol. 2004;171(6):2341–5. doi: 10.1097/01.ju.0000125198.32936.38 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref041] 41.Schooling CM, Yeung SLA, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11(1):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref042] 42.Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5–15. doi: 10.3109/13685538.2015.1004049 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref043] 43.Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005;63(3):239–50. doi: 10.1111/j.1365-2265.2005.02299.x [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref044] 44.Hackett G. Type 2 Diabetes and Testosterone Therapy. World J Mens Health. 2019;37(1):31. doi: 10.5534/wjmh.180027 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgph.0000052.ref045] 45.Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros J, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl. 2005;28(3):125–7. doi: 10.1111/j.1365-2605.2005.00553.x [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref046] 46.Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Valkonen V-P, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005;90(2):712–9. doi: 10.1210/jc.2004-0970 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref047] 47.Trummer H, Habermann H, Haas J, Pummer K. The impact of cigarette smoking on human semen parameters and hormones. Hum Reprod. 2002;17(6):1554–9. doi: 10.1093/humrep/17.6.1554 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref048] 48.Onahn CE, Meludu SC, Dioka CE, Onuegbu JA. Pattern of male sex hormones in type 2 diabetic patients in Nnewi, South Eastern Nigeria. IOSR-JDMS. 2013;10(4):65–70. [Google Scholar]

[pgph.0000052.ref049] 49.Saboor Aftab SA, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol (Oxf). 2013;78(3):330–7. doi: 10.1111/cen.12092 [DOI] [PubMed] [Google Scholar]

[pgph.0000052.ref050] 50.Tripathy D, Dhindsa S, Garg R, Khaishagi A, Syed T, Dandona P. Hypogonadotropic hypogonadism in erectile dysfunction associated with type 2 diabetes mellitus: a common defect? Metab Syndr Relat Disord. 2003;1(1):75–80. doi: 10.1089/154041903321648270 [DOI] [PubMed] [Google Scholar]

PERMALINK

Prevalence and determinants of low testosterone levels in men with type 2 diabetes mellitus; a case-control study in a district hospital in Ghana

Dorcas Serwaa

Folasade Adenike Bello

Kayode O Osungbade

Charles Nkansah

Felix Osei-Boakye

Samuel Kwasi Appiah

Maxwell Hubert Antwi

Mark Danquah

Tonnies Abeku Buckman

Ernest Owusu

Roles

Abstract

Introduction

Subjects and methods

Study design and study setting

Study participants

Sample size determination

Collection of information and patients selection

Anthropometric variables measurements

Body mass index

Blood pressure (using Korotkoff 1 and 5)

Physical activities

Sexual health inventory for men (SHIM) questionnaire

Health-related quality of life questionnaire

Fasting blood glucose (FBG) measurement

Blood sample collection

Laboratory assay (FSH, LH and testosterone estimation)

Ethical consideration and informed consent

Statistical analysis

Results

Table 1. Baseline characteristics of the study participants.

Table 2. Clinical and hormonal parameters of the study population.

Correlation of testosterone (T) with fasting blood sugar among the participants

Fig 1. Correlation between testosterone levels and fasting blood glucose.

Correlation of testosterone (T) with glycated hemoglobin (HbA1c) among the participants

Fig 2. Correlation between testosterone levels and glycated hemoglobin (HbA1c) levels among the study participants.

Prevalence of hypogonadism in the study population

Fig 3. Percentage distribution of categorized testosterone levels.

Clinical and hormonal parameters of type 2 diabetic and the healthy hypogonadal men

Table 3. Clinical and hormonal parameters of type 2 diabetic and healthy hypogonadal men.

Binary and multivariable logistic regression about determinants of hypogonadism among the study participants

Table 4. Binary and multivariate logistic regression of sociodemographic, clinical and lifestyle factors associated of hypogonadism in the study participants.

Discussion

Conclusion

Supporting information

Acknowledgments

Data Availability

Funding Statement

References

Decision Letter 0

Palash Chandra Banik

Julia Robinson

Roles

Author response to Decision Letter 0

Decision Letter 1

Palash Chandra Banik

Julia Robinson

Roles

Author response to Decision Letter 1

Decision Letter 2

Palash Chandra Banik

Julia Robinson

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases